FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Glenmark Pharmaceuticals Rizatriptan Benzoate Orally Disintegrating Recall

Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5mg, 18 (3 x 6) Unit-Dose Table…

Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ

Risk level
Class II
Reported by FDA
Jun 12, 2024
Recall ID
D-0534-2024
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Rizatriptan Benzoate Orally Disintegrating starting May 13, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0534-2024 on Jun 12, 2024. Reason: CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit. Status: Ongoing.

Why it was recalled

CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.

Product description

Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5mg, 18 (3 x 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-467-06

Lot numbers, UPCs & expiration codes

Lot#: 19224857; Exp. 11/2024 Lot#: 19232493; Exp. 6/2025

Where it was sold

US Nationwide.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0534-2024
Classification
Class II
Status
Ongoing
Recall initiated
May 13, 2024
FDA report date
Jun 12, 2024
Quantity
2400 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-0534-2024, exactly as published.

Show all FDA fields
City
Mahwah
State
NJ
Status
Ongoing
Country
United States
Event ID
94608
Address
750 Corporate Dr
Code information
Lot#: 19224857; Exp. 11/2024 Lot#: 19232493; Exp. 6/2025
Postal code
07430-2009
Report date
Jun 12, 2024
Product type
Drugs
Recall number
D-0534-2024
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Product quantity
2400 cartons
Reason for recall
CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5mg, 18 (3 x 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-467-06
Distribution pattern
US Nationwide.
Recall initiation date
May 13, 2024
Initial firm notification
Letter
Center classification date
Jun 4, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0534-2024, published Jun 12, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls